Aduro Biotech (ADRO), Novartis AG (NVS) Report Data from Ongoing Phase 1b Study of STING Agonist ADU-S100 (MIW815) in Combination with Anti-PD-1 Monoclonal Antibody Spartalizumab (PDR001)
Tweet Send to a Friend
Aduro Biotech, Inc. (NASDAQ: ADRO) announced the presentation of data from an ongoing Phase 1b clinical trial in collaboration with ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
